Clovis Oncology, Inc. (CLVS) Earns "Hold" Rating from Cann

James Marshall
August 4, 2017

The company is now entering phase 3 trials for its ARIEL3 study, which involves using Rubraca for the treatment of ovarian cancer. Promising progression-free survival and safety results from the ARIEL3 maintenance study will help expand Rubraca's label, thereby improving the commercial uptake of the drug.

"We believe this bodes well for our broader maintenance label that would address this larger population, if approved by the FDA next year", said Clovis CEO Patrick Mahaffy on the company's earnings call Thursday. Rubraca is set to face intense competition from now marketed PARP inhibitors. Earnings, adjusted for one-time gains and costs, were 84 cents per share. (NASDAQ:CLVS). According to the most recently released broker notes, 4 analysts have a rating of "strong buy" on the stock, 5 analysts "buy", 4 analysts "neutral", 0 analysts "sell" and 0 analysts "strong sell". Bank of America Corporation restated a "buy" rating on shares of Clovis Oncology in a research report on Thursday. 762,571 shares of the company's stock traded hands. Credit Suisse Group reaffirmed an "outperform" rating and set a $74.00 target price on shares of Clovis Oncology in a research report on Tuesday, April 18th.

06/20/2017 - Clovis Oncology, Inc. had its " rating reiterated by analysts at Morgan Stanley. The stock of Clovis Oncology Inc (NASDAQ:CLVS) earned "Sell" rating by Chardan Capital Markets on Tuesday, October 25. Eight analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. CLVS's current price-earnings ratio amounts above the average P/E ratio of 160.62 times earnings. Clovis Oncology Inc (NASDAQ:CLVS) has risen 282.71% since August 2, 2016 and is uptrending. The company has a 50-day moving average of $87.51 and a 200-day moving average of $66.24. Clovis Oncology has a 52 week low of $14.62 and a 52 week high of $99.45. The stock's market capitalization is $3.67 billion.

The consensus analysts recommendation at this point stands at 2.00 on Clovis Oncology, Inc. The biopharmaceutical company reported ($1.33) EPS for the quarter, topping analysts' consensus estimates of ($1.43) by $0.10. The company had revenue of $14.62 million for the quarter, compared to analysts' expectations of $13.07 million. The average volume for Clovis Oncology, Inc. During the same period in the prior year, the company posted ($2.07) EPS. Ghost Tree Capital Ltd Limited Liability Company reported 220,000 shares. Price T Rowe Associates Inc Md reported 439,406 shares stake. "(CLVS) Upgraded to Buy by Zacks Investment Research" was first published by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of USA and worldwide copyright and trademark legislation. The legal version of this report can be viewed at The total volume traded for the day is 2.36 million, as compared to its average daily volume of 228,725 shares. Following the sale, the insider now owns 200,583 shares in the company, valued at $12,400,041.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The stock spiked 8.37% last month and is up 41.8 this year. Company insiders own 17.40% of the company's stock.

Several institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new stake in Clovis Oncology during the fourth quarter valued at approximately $3,647,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Clovis Oncology by 71.4% in the first quarter. Clough Capital Partners L P now owns 15,900 shares of the biopharmaceutical company's stock worth $1,012,000 after buying an additional 100 shares during the last quarter. Wellington Management Group LLP boosted its stake in Clovis Oncology by 10,143.6% in the first quarter. Teachers Advisors LLC now owns 491,094 shares of the biopharmaceutical company's stock valued at $31,268,000 after buying an additional 70,582 shares in the last quarter. Shell Asset Management Co. purchased a new position in Clovis Oncology during the first quarter valued at $489,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. raised its position in shares of Clovis Oncology by 209.0% in the second quarter. BNP Paribas Arbitrage SA now owns 5,250 shares of the biopharmaceutical company's stock valued at $492,000 after buying an additional 4,446 shares during the period.

Other reports by Click Lancashire

Discuss This Article